Table 2.
Treatment details
| Mean follow-up period post-MMF initiation (months) (mean±SD) | 39.0±23.9 |
| Mean treatment length (months) (mean±SD) | 19.2±14.0 |
| Maximum dose | |
| 1 g | 2 (2) |
| 2 g | 41 (42) |
| 3 g | 52 (53) |
| Other | 3 (3): 0.5 g (1); 1.5 g (1); 2.5 g (1) |
| Side effects | |
| Infection | 11 (11) |
| Anaemia | 2 (2) |
| Nausea/vomiting | 6 (6) |
| Abdominal pain | 3 (3) |
| Diarrhoea | 6 (6) |
| Increased reflux symptoms | 4 (4) |
| Pseudo-obstruction | 2 (2) |
| Headache | 1 (1) |
| Medications prior to MMF | 41 (42) |
| Corticosteroids | 30 (31) |
| Azathioprine | 4 (4) |
| Cyclophosphamide | 9 (9) |
| d-Penicillamine | 11 (11) |
| IVIG | 0 |
| Methotrexate | 23 (23) |
| Medications used in conjunction with MMF | 28 (29) |
| Corticosteroids | 21 (21) |
| Azathioprine | 0 |
| Cyclophosphamide | 0 |
| d-Penicillamine | 0 |
| IVIG | 11 (11) |
| Methotrexate | 17 (17) |
All values are n (%) unless stated otherwise.
IVIG, intravenous immunoglobulins; MMF, mycophenolate mofetil.